BridgeBio Pharma (NASDAQ:BBIO) CAO Sells $143,160.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CAO Maricel Apuli sold 2,000 shares of the stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $71.58, for a total value of $143,160.00. Following the transaction, the chief accounting officer directly owned 134,115 shares of the company’s stock, valued at $9,599,951.70. This trade represents a 1.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maricel Apuli also recently made the following trade(s):

• On Tuesday, February 17th, Maricel Apuli sold 510 shares of BridgeBio Pharma stock. The stock was sold at an average price of $74.31, for a total value of $37,898.10.

BridgeBio Pharma Trading Down 1.0%

NASDAQ:BBIO opened at $68.09 on Thursday. The stock has a market capitalization of $13.33 billion, a PE ratio of -18.01 and a beta of 1.02. BridgeBio Pharma, Inc. has a 1-year low of $31.77 and a 1-year high of $84.94. The firm has a fifty day simple moving average of $71.29 and a 200 day simple moving average of $71.23.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The business had revenue of $154.18 million for the quarter, compared to analysts’ expectations of $150.71 million. During the same quarter in the prior year, the business earned ($1.40) earnings per share. The company’s quarterly revenue was up 2521.2% on a year-over-year basis. On average, equities analysts predict that BridgeBio Pharma, Inc. will post -2.05 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on BBIO. Royal Bank Of Canada assumed coverage on BridgeBio Pharma in a research note on Thursday, April 9th. They issued an “outperform” rating and a $100.00 price objective on the stock. JPMorgan Chase & Co. upped their price target on shares of BridgeBio Pharma from $89.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, March 10th. William Blair started coverage on shares of BridgeBio Pharma in a report on Tuesday, March 10th. They issued an “outperform” rating on the stock. Leerink Partners restated an “outperform” rating and set a $98.00 price objective on shares of BridgeBio Pharma in a report on Thursday, March 12th. Finally, Mizuho restated an “outperform” rating and issued a $106.00 price target on shares of BridgeBio Pharma in a research note on Tuesday, April 28th. Twenty-four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $87.71.

Institutional Investors Weigh In On BridgeBio Pharma

A number of large investors have recently added to or reduced their stakes in BBIO. Vanguard Group Inc. lifted its position in shares of BridgeBio Pharma by 2.1% during the 3rd quarter. Vanguard Group Inc. now owns 16,832,059 shares of the company’s stock valued at $874,257,000 after acquiring an additional 347,074 shares during the period. Janus Henderson Group PLC lifted its position in BridgeBio Pharma by 25.8% during the fourth quarter. Janus Henderson Group PLC now owns 11,000,457 shares of the company’s stock worth $841,349,000 after purchasing an additional 2,259,378 shares during the period. Farallon Capital Management LLC grew its stake in BridgeBio Pharma by 9.8% during the fourth quarter. Farallon Capital Management LLC now owns 8,998,463 shares of the company’s stock worth $688,292,000 after buying an additional 806,463 shares in the last quarter. Aisling Capital Management LP grew its stake in BridgeBio Pharma by 0.4% during the third quarter. Aisling Capital Management LP now owns 6,089,611 shares of the company’s stock worth $316,294,000 after buying an additional 21,486 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in BridgeBio Pharma by 23.0% in the 4th quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock valued at $369,547,000 after buying an additional 902,648 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.